Cost-Effectiveness Analysis of Ipilimumab in Previously Untreated Patients With Unresectable Malignant Melanoma in Scotland.

نویسندگان

  • D Lee
  • J Porter
  • A J Hatswell
  • N Hertel
  • A Walker
چکیده

• The survival outcomes for first-line ipilimumab were modelled, in the SMC base case model, using data from the Phase III RCT CA184-024, due to local requirements of the SMC. However, as the CA184-024 trial contained an unlicensed 10mg/kg dose of ipilimumab and the combination with DTIC (licensed dose is 3mg/kg), multiple sources were used to produce a range of reliable estimates of the incremental cost-effectiveness ratio (ICER) for ipilimumab:

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic mela...

متن کامل

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma

Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg ever...

متن کامل

A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

Background Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the sponsor entering a 'managed entry scheme' to assess the 2-year overall survival rate in metastatic melanoma patients who received ipilimumab in the first year of Pharmaceutical Benefits Scheme listing. Methods All unresectable stage IIIc / IV metastatic me...

متن کامل

Cost-Effectiveness of Pembrolizumab for Unresectable Metastatic Melanoma After Progression with Ipilimumab in England.

REFERENCES Pembrolizumab (MK-3475) is a humanised, anti-programmed cell death 1 (PD-1) monoclonal IgG4 antibody. It is involved in the blockade of immune suppression and reactivation of anergic T-cells in cancer patients. It is believed that due to the high specificity and affinity for PD-1, against which it displays pure antagonist properties, pembrolizumab has the potential to improve the eff...

متن کامل

A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.

PURPOSE The aim of this study was to evaluate the cost-effectiveness of nivolumab versus ipilimumab for the treatment of previously untreated patients with BRAF-advanced melanoma (BRAF-AM) from an Australian health system perspective. METHODS A state-transition Markov model was constructed to simulate the progress of Australian patients with BRAF-AM. The model had a 10-year time horizon with ...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

دوره 17 7  شماره 

صفحات  -

تاریخ انتشار 2014